NACLC 2025

Expert clinical insights from NACLC 2025 in non–small cell lung cancer, focusing on emerging data, evolving treatment strategies, and practice-changing developments. It emphasizes translating key conference findings into real-world clinical decision-making and patient care.

EP. 5: Closing Perspectives on Advancing Care in EGFR-Positive NSCLC

Joshua Sabari, MD, Danny Nguyen, MD, Edgardo Santos Castillero, MD, FACP, FASCO, Eric Singhi, MD, Alexander Spira, MD, PhD, FACP, FASCO

Ep. 4: Managing Toxicities in MARIPOSA: Mitigating Treatment-Related Adverse Events

Joshua Sabari, MD, Danny Nguyen, MD, Edgardo Santos Castillero, MD, FACP, FASCO, Eric Singhi, MD, Alexander Spira, MD, PhD, FACP, FASCO

Ep. 3: Clinical Insights: Escalation vs De-escalation in EGFR-Positive NSCLC

Joshua Sabari, MD, Danny Nguyen, MD, Edgardo Santos Castillero, MD, FACP, FASCO, Eric Singhi, MD, Alexander Spira, MD, PhD, FACP, FASCO

Ep. 2: CNS Control and Resistance: Panel Examines Amivantamab Plus Lazertinib

Joshua Sabari, MD, Danny Nguyen, MD, Edgardo Santos Castillero, MD, FACP, FASCO, Eric Singhi, MD, Alexander Spira, MD, PhD, FACP, FASCO

Ep. 1: Overall Survival Updates in EGFR-Positive NSCLC: MARIPOSA and FLAURA2

Joshua Sabari, MD, Danny Nguyen, MD, Edgardo Santos Castillero, MD, FACP, FASCO, Eric Singhi, MD, Alexander Spira, MD, PhD, FACP, FASCO

Clinical Insights: Metastatic EGFR+ NSCLC from MARIPOSA and PALOMA-3

Joshua Sabari, MD, Alexander Spira, MD, PhD, FACP, FASCO, Danny Nguyen, MD, Edgardo Santos Castillero, MD, FACP, FASCO, Eric Singhi, MD